COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Sedation/Cognition/EEG Study Using AZD6280 and Comparator

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00750802
Recruitment Status : Completed
First Posted : September 11, 2008
Last Update Posted : June 26, 2009
Information provided by:

Brief Summary:
The purpose of the study is to determine the effects of AZD6280 compared to lorazepam on sleepiness, concentration and brain activity.

Condition or disease Intervention/treatment Phase
Healthy Volunteer Drug: AZD6280 Drug: Lorazepam Drug: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 17 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: A Phase 1, Single Centre, Single Dose, Double-Blind, Double-Dummy, Four-Way Crossover, Placebo-Controlled, Randomized Study to Investigate the Effects of AZD6280 on Sedation, Cognition and EEG in Comparison With Lorazepam in Healthy Male Volunteers
Study Start Date : September 2008
Actual Study Completion Date : December 2008

Resource links provided by the National Library of Medicine

Drug Information available for: Lorazepam

Arm Intervention/treatment
Experimental: 1 Drug: AZD6280
10mg Capsule, oral, single-dose

Experimental: 2 Drug: AZD6280
40mg Capsule, oral, single-dose

Active Comparator: 3 Drug: Lorazepam
2mg tablet, oral single-dose
Other Name: Ativan

Placebo Comparator: 4 Drug: Placebo

Primary Outcome Measures :
  1. Evaluation of the pharmacodynamic effects of AZD6280 by central nervous system function tests [ Time Frame: Test batteries will be performed at specified times both before and following study drug administration ]

Secondary Outcome Measures :
  1. Evaluation and characterization of the pharmacokinetics of AZD6280 [ Time Frame: Blood samples will be taken during the study. ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy male and female subjects aged 18 to 55 years (inclusive) on Day 1.
  • Female subjects must be of non-child bearing potential.

Exclusion Criteria:

  • Clinically significant illness within 2 weeks before the study start.
  • Enrollment in another concurrent investigational study or intake of an investigational drug within 30 days or intake of an investigational drug within a period of 5 half lives of that drug prior to the screening visit
  • Blood loss in excess of 200 mL within 30 days of Day -2, in excess of 400 mL within 90 days of Day -2, or in excess of 1200 mL within 1 year of Day -2
  • Clinically relevant abnormalities in physical examinations, vital signs, ECG, clinical chemistry, hematology or urinalysis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00750802

Layout table for location information
Research Site
Leiden, Netherlands
Sponsors and Collaborators
Layout table for additonal information
Responsible Party: Mark Smith, MD, MSD, Emerging Psychiatry, AstraZeneca Pharmaceuticals Identifier: NCT00750802    
Other Study ID Numbers: D0850C00014
Eudract # 2008-001757-17
First Posted: September 11, 2008    Key Record Dates
Last Update Posted: June 26, 2009
Last Verified: June 2009
Keywords provided by AstraZeneca:
Phase I
Additional relevant MeSH terms:
Layout table for MeSH terms
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Hypnotics and Sedatives
Central Nervous System Depressants
Anti-Anxiety Agents
Tranquilizing Agents
Psychotropic Drugs
GABA Modulators
GABA Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action